Transplantation therapy is provided in cooperation with the Department of Hematology and Oncology and the hematology and oncology group of the Department of Pediatrics. In particularly close cooperation with the Depertment of Blood Transfusion and the Radiology, as well as with specialized departments to treat various posttransplant complications, the Department of Cell Therapy and Transplantation Medicine provides comprehensive and intensive therapy.

Treatment plans for adult patients are determined jointly with the Department of Hematology and Oncology and plans for pediatric patients are determined jointly with the hematology and oncology group of the Department of Pediatrics. Bone marrow, the source of transplantation, is collected jointly with the Surgical Center and peripheral blood stem cells are collected jointly with the Blood Transfusion Department.

■Hematopoietic stem cell transplantation (autologous, bone marrow, peripheral blood stem cell, umbilical cord blood, HLA haploidentical)
Hematopoietic stem cell transplantation is a treatment in which hematopoietic stem cells collected from a patient’s own peripheral blood or from a donor are infused after high-dose chemotherapy or radiation therapy. The department is actively performing this procedure to achieve a cure. It has performed numerous autologous transplants for various diseases such as malignant lymphoma, multiple myeloma, and CNS lymphoma. The same applies for allogeneic transplants. The department also performs special transplantation treatments, such as non-myeloablative allogeneic stem cell transplants (also known as mini-transplants) for elderly patients over 65 years old and HLA haploidentical transplants, a method that has been developed recently. Haploidentical transplants are attracting attention because they can be performed from a donor with only a half-matched HLA, allowing patients to find a match in a short period of time.

■CAR T-cell therapy
CAR T-cell therapy is garnering attention as the latest immuno-cell therapy for hematologic tumors. We work with the Deepartment of Hematology and Oncology, Pediatrics, and Blood Transfusion, as well as the Cell Processing Center, to ensure the safe operation of CAR T-cell therapy.

Acute myelogenous leukemia, acute lymphoblastic leukemia, aplastic anemia,myelodysplastic syndrome, malignant lymphoma, congenital immunodeficiency syndrome multiple myeloma, pediatric cancer, germ cell tumors, adrenoleukodystrophy, etc.